Company Cellectar Biosciences, Inc.

CLRB

US15117F8077

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:07:07 2024-05-15 pm EDT			5-day change	1st Jan Change
3.35 ^USD	+5.35%		+4.38%	+20.58%

May. 14	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstromâs macroglobulinemia (WM).

Number of employees: 20

Managers	Title	Age	Since
James V. Caruso CEO	Chief Executive Officer	65	15-06-14
Chad J. Kolean DFI	Director of Finance/CFO	59	14-05-27
Andrei Shustov CTO	Chief Tech/Sci/R&D Officer	-	23-02-14
Jarrod Longcor COO	Chief Operating Officer	51	16-07-14
Shane Lea PRN	Corporate Officer/Principal	-	22-11-20

Members of the board	Title	Age	Since
Fred Driscoll BRD	Director/Board Member	74	17-04-06
Douglas Swirsky CHM	Chairman	54	17-04-06
John Neis BRD	Director/Board Member	68	08-01-31
James V. Caruso CEO	Chief Executive Officer	65	15-06-14
Stefan Loren BRD	Director/Board Member	60	15-06-14
Asher Chanan-Khan BRD	Director/Board Member	55	21-06-23

	Vote	Quantity	Free-Float	Total Float
Stock A	0	320	0	88.19 %
Stock B	0	111	0
Stock C	0	1,237	0
Stock D	1	32,260,510	28,450,306 ( 88.19 %)

Name	Equities	%	Valuation
Rosalind Advisors, Inc. 9.222 %	3,305,936	9.222 %	10 M $
AIGH Capital Management LLC 7.824 %	2,804,917	7.824 %	8 M $
AIGH Capital Management LLC 7.427 %	2,662,324	7.427 %	8 M $
Adar1 Capital Management LLC 5.088 %	1,824,063	5.088 %	6 M $
Adar1 Capital Management LLC 3.844 %	1,378,082	3.844 %	4 M $
Nantahala Capital Management LLC 3.767 %	1,350,578	3.767 %	4 M $
Vanguard Global Advisers LLC 3.323 %	1,191,081	3.323 %	4 M $
Laurence Lytton 2.504 %	897,605	2.504 %	3 M $
Rosalind Advisors, Inc. 1.734 %	621,478	1.734 %	2 M $
Acuta Capital Partners LLC 1.332 %	477,500	1.332 %	1 M $

Name	Equities	%	Valuation
Skaana Management LP -	0	-	- $

Cellectar Biosciences, Inc.

100 Campus Drive

07932, Florham Park

+608 441 8120

http://www.cellectar.com

address Cellectar Biosciences, Inc.(CLRB)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.18 USD

Average target price

15 USD

Spread / Average Target

+371.70%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
CELLECTAR BIOSCIENCES, INC.	+20.58%	114M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.81%	364B
MERCK & CO., INC.	+20.35%	326B
ABBVIE INC.	+5.40%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+11.03%	167B
PFIZER, INC.	-0.04%	161B

Other Pharmaceuticals